A phase II/III study of BHV-0223 for the treatment of spinocerebellar ataxia.
Phase of Trial: Phase II/III
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Riluzole (Primary)
- Indications Spinocerebellar ataxias
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2016 According to Biohaven Pharmaceutical media release, company plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.
- 11 Mar 2016 New trial record
- 03 Mar 2016 According to a Biohaven media release, the company expects to initiate this trial of BHV-0223 for the treatment of spinocerebellar ataxia before the end of 2016.